GlassScriptPhysician profile
David M Netherton
NPI 1356345813
$5,244.73
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,783 · 2020: $2,065 · 2021: $1,309 · 2022: $57.13 · 2023: $30.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $889.77 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $581.07 | 2019-2021 | |
| Amgen INC. | $381.11 | 2019-2021 | |
| Abbvie INC. | $357.19 | 2019-2021 | |
| Lilly USA, LLC | $347.86 | 2019-2021 | |
| Pfizer INC. | $337.88 | 2019-2021 | |
| Amarin Pharma, INC. | $255.85 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $219.33 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.61 | 2019-2020 | |
| Allergan, INC. | $177.64 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $158.71 | 2019 | |
| Eisai INC. | $149.88 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $136.35 | 2019-2020 | |
| Radius Health, INC. | $115.85 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $103.34 | 2020-2023 | Qelbree |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $94.48 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $84.54 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.45 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.62 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $61.26 | 2021 | |
| Janssen Pharmaceuticals, INC | $58.72 | 2019-2021 | |
| Lundbeck LLC | $47.77 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $46.29 | 2020-2021 | |
| Daiichi Sankyo INC. | $41.42 | 2019-2021 | |
| Almatica Pharma LLC | $36.82 | 2021 | |
| Shire North American Group INC | $28.34 | 2019 | |
| Arbor Pharmaceuticals, INC. | $25.92 | 2019-2020 | |
| Esperion Therapeutics, INC. | $23.78 | 2020-2021 | |
| Dexcom, INC. | $18.90 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.13 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.65 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $13.71 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.59 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.56 | 2020 | |
| Genentech USA, INC. | $12.84 | 2019 | |
| Mylan Specialty L.P. | $11.41 | 2020 | |
| Glaxosmithkline, LLC. | $11.18 | 2020 | |
| Vivus LLC | $3.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Netherton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.